Coordinate Modulation of Glycolytic Enzymes and OXPHOS by Imatinib in BCR-ABL Driven Chronic Myelogenous Leukemia Cells

Since many oncogenes, including BCR-ABL, may promote the acquisition and maintenance of the glycolytic phenotype, we tested whether treatment of BCR-ABL-driven human leukemia cells with imatinib, a selective BCR-ABL inhibitor, can modulate the expression of key glycolytic enzymes and mitochondrial c...

Descripción completa

Detalles Bibliográficos
Autores principales: De Rosa, Viviana, Monti, Marcello, Terlizzi, Cristina, Fonti, Rosa, Del Vecchio, Silvana, Iommelli, Francesca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6651622/
https://www.ncbi.nlm.nih.gov/pubmed/31252559
http://dx.doi.org/10.3390/ijms20133134

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6651622/
https://www.ncbi.nlm.nih.gov/pubmed/31252559
http://dx.doi.org/10.3390/ijms20133134

Ejemplares similares